Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06505018 | Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients…(ALTERNATIVE) | N/A | terminated | Jul 17, 2024 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment. | Enrollment / accrual |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular… | Phase 2 | terminated | Sep 30, 2020 | Mayo Clinic | grant and funding expired | Funding |
| NCT05384119 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone… | Phase 1 | terminated | May 20, 2022 | Tvardi Therapeutics, Incorporated | The study was terminated prior to Phase 2 due to slow accrual. | Enrollment / accrual |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative,…(SOBER) | Phase 2 | terminated | Dec 11, 2017 | Ruijin Hospital | Due to slower than anticipated enrollment, the study was terminated early after 78 patients were… | Enrollment / accrual |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06560385 | Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula | N/A | terminated | Aug 19, 2024 | GenieBiome Limited | No enough subjects within the recruitment period | Enrollment / accrual |
| NCT01613482 | TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention(TSARINE) | Phase 3 | terminated | Jun 7, 2012 | Centre Oscar Lambret | Lack of enrollment | Enrollment / accrual |
| NCT02926729 | Real-Time Assessment Of Breast Cancer Surgical Specimen Margins With Nonlinear Microscopy | N/A | terminated | Oct 6, 2016 | Beth Israel Deaconess Medical Center | Low enrollment | Enrollment / accrual |
| NCT07814365 | PBI for Low-risk Breast Cancer | N/A | withdrawn | Sep 11, 2026 | Fudan University | funding issue | Funding |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT05076266 | COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151)… | — | terminated | Oct 13, 2021 | Eastern Cooperative Oncology Group | slower than expected accrual. | Enrollment / accrual |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT06274034 | MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors | Early Phase 1 | terminated | Feb 23, 2024 | Mayo Clinic | Funds expired | Funding |
| NCT07805538 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy | N/A | withdrawn | Sep 4, 2026 | Fudan University | funding issues and poor accrual | Enrollment / accrual |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast… | Phase 2 / Phase 3 | suspended | Mar 13, 2017 | M.D. Anderson Cancer Center | PI Requested | Other (stated, no rule matched) |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… | Phase 2 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT07644702 | WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial… | N/A | terminated | Jun 12, 2026 | Mayo Clinic | Unable to reach enrollment target before the forum date of 9/17/2026 | Enrollment / accrual |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 6, 2023 | Roswell Park Cancer Institute | Funding ended | Funding |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | N/A | suspended | Dec 14, 2016 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT07214662 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… | Phase 1 | terminated | Oct 9, 2025 | Genentech, Inc. | The trial was terminated due to sponsor decision. | Sponsor / business decision |
| NCT04803084 | Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment | — | suspended | Mar 17, 2021 | Laura Kennedy | MRI upgrade | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or…(KOMODO-1) | Phase 1 | terminated | Feb 12, 2026 | Boundless Bio, Inc. | The study was terminated primarily due to a business decision related to a corporate transaction… | Safety / toxicity |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT07173101 | Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on…(HEADBAND) | Phase 2 | terminated | Sep 15, 2025 | University of Utah | Safety Review | Safety / toxicity |
| NCT06052345 | Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors,…(CIPN-REBECCA) | — | withdrawn | Sep 25, 2023 | Theodoros Foukakis | No accrual | Enrollment / accrual |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT02393833 | IBCSG Trial 22-00 Serum Substudy | N/A | terminated | Mar 19, 2015 | ETOP IBCSG Partners Foundation | Sufficient statistical power cannot be met due to low samples size | Other (stated, no rule matched) |
| NCT06162663 | Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for… | Phase 4 | terminated | Dec 8, 2023 | Medical University of South Carolina | Terminated early due to insufficient accrual to meet prespecified statistical analysis requirements. | Enrollment / accrual |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | N/A | withdrawn | Sep 24, 2024 | Scripps Health | no patients were able to be enrolled | Enrollment / accrual |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT07165756 | "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the…(MaVie) | — | terminated | Sep 10, 2025 | Institut de Cancérologie de Lorraine | Principal Investigator's departure | Investigator |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to… | Phase 1 | suspended | Jan 6, 2023 | National Cancer Institute (NCI) | Other - DLT assessment and phase 2 dose determination | Other (stated, no rule matched) |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in…(AIPAC-003) | Phase 2 / Phase 3 | terminated | Feb 28, 2023 | Immutep S.A.S. | Sponsor Decision | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT04364672 | Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive… | Phase 1 | withdrawn | Apr 28, 2020 | University of Alabama at Birmingham | lack of recruitment and funding | Enrollment / accrual |
| NCT05754749 | Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | Early Phase 1 | terminated | Mar 6, 2023 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase 1 / Phase 2 | terminated | Jan 6, 2022 | Genmab | The Sponsor has made a strategic decision to stop the development of GEN1047. | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or…(ELONA) | Phase 1 / Phase 2 | terminated | Nov 16, 2022 | Context Therapeutics Inc. | Sponsor decision to discontinue onapristone development. | Sponsor / business decision |
| NCT05823467 | What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing… | N/A | terminated | Apr 21, 2023 | University of Alberta | Logistical Issues | Other (stated, no rule matched) |
| NCT06060561 | Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy | — | suspended | Sep 29, 2023 | Mayo Clinic | on hold for analysis | Other (stated, no rule matched) |
| NCT07441330 | Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission… | N/A | terminated | Feb 27, 2026 | GCS Ramsay Santé pour l'Enseignement et la Recherche | difficulty in including patients | Other (stated, no rule matched) |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced… | Phase 2 | suspended | Aug 5, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials